The cancer-immunity cycle provides a framework to understand the series of events that
generate anti-cancer immune responses. It emphasizes the iterative nature of the response …

The human microbiome constitutes a complex multikingdom community that symbiotically
interacts with the host across multiple body sites. Host-microbiome interactions impact …

The use of probiotics by cancer patients is increasing, including among those undergoing
immune checkpoint inhibitor (ICI) treatment. Here, we elucidate a critical microbial-host …

Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs)
in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we …

CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Growing evidence suggests that the gut microbiota modulates the efficacy and toxicity of
cancer therapy, most notably immunotherapy and its immune-related adverse effects. The …

Checkpoint inhibitors are being added to standard-of-care chemotherapy in multiple clinical
trials. Success has been reported in non–small and small cell lung carcinomas and …

Reinvigoration of antitumor immunity remains an unmet challenge. Our retrospective
analyses revealed that cancer patients who took antihistamines during immunotherapy …

The intricacy of diseases, shaped by intrinsic processes like immune system exhaustion and
hyperactivation, highlights the potential of immune renormalization as a promising strategy …

Antibiotics (ABX) compromise the efficacy of programmed cell death protein 1 (PD-1)
blockade in cancer patients, but the mechanisms underlying their immunosuppressive …